Arbutus Biopharma Corporation ABUS FX Effect on Cash
FX Effect on Cash at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's fx effect on cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's FX effect on cash?
- Arbutus Biopharma Corporation (ABUS) reported FX effect on cash of -$10K in Q1 2026.
- How has Arbutus Biopharma Corporation's FX effect on cash changed year-over-year?
- Arbutus Biopharma Corporation's FX effect on cash decreased by 350.0% year-over-year, from $4K to -$10K.
- What is the long-term trend for Arbutus Biopharma Corporation's FX effect on cash?
- Over 2 years (2021 to 2023), Arbutus Biopharma Corporation's FX effect on cash has grown at a 128.0% compound annual growth rate (CAGR), from $5K to $26K.
- What does FX effect on cash mean?
- The impact of exchange rate changes on the value of cash and equivalents held in foreign currencies.